JPWO2020035779A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020035779A5 JPWO2020035779A5 JP2021507613A JP2021507613A JPWO2020035779A5 JP WO2020035779 A5 JPWO2020035779 A5 JP WO2020035779A5 JP 2021507613 A JP2021507613 A JP 2021507613A JP 2021507613 A JP2021507613 A JP 2021507613A JP WO2020035779 A5 JPWO2020035779 A5 JP WO2020035779A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- carcinoma
- hydrogen
- cell carcinoma
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862765138P | 2018-08-17 | 2018-08-17 | |
US62/765,138 | 2018-08-17 | ||
PCT/IB2019/056847 WO2020035779A1 (en) | 2018-08-17 | 2019-08-12 | Urea compounds and compositions as smarca2/brm atpase inhibitors |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2021534147A JP2021534147A (ja) | 2021-12-09 |
JPWO2020035779A5 true JPWO2020035779A5 (es) | 2022-08-17 |
JP7328323B2 JP7328323B2 (ja) | 2023-08-16 |
Family
ID=68072895
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021507613A Active JP7328323B2 (ja) | 2018-08-17 | 2019-08-12 | SMARCA2/BRM ATPase阻害剤としての尿素化合物及び組成物 |
Country Status (21)
Country | Link |
---|---|
US (1) | US11958846B2 (es) |
EP (2) | EP4219488A1 (es) |
JP (1) | JP7328323B2 (es) |
KR (1) | KR20210047313A (es) |
CN (1) | CN112585136B (es) |
AU (1) | AU2019322325B2 (es) |
BR (1) | BR112021002632A2 (es) |
CA (1) | CA3107097A1 (es) |
CY (1) | CY1126039T1 (es) |
DK (1) | DK3837256T3 (es) |
ES (1) | ES2946060T3 (es) |
FI (1) | FI3837256T3 (es) |
HR (1) | HRP20230477T1 (es) |
HU (1) | HUE061963T2 (es) |
LT (1) | LT3837256T (es) |
MX (1) | MX2021001804A (es) |
PL (1) | PL3837256T3 (es) |
PT (1) | PT3837256T (es) |
RS (1) | RS64238B1 (es) |
SI (1) | SI3837256T1 (es) |
WO (1) | WO2020035779A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11497752B2 (en) | 2018-01-30 | 2022-11-15 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
BR112022015004A2 (pt) | 2020-01-29 | 2022-09-20 | Foghorn Therapeutics Inc | Composto, composição farmacêutica, métodos para diminuir a atividade de um complexo baf, induzir apoptose, reduzir o crescimento tumoral, suprimir a progressão e a colonização metastática do câncer e reduzir o nível e/ou a atividade de brg1 e/ou brm em um câncer e métodos de tratamento e de inibição de brm e brg1 |
CN112979646B (zh) * | 2021-03-08 | 2022-01-14 | 北京富龙康泰生物技术有限公司 | 一种咪唑并吡啶类衍生物 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2779780A (en) | 1955-03-01 | 1957-01-29 | Du Pont | 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation |
AUPP003197A0 (en) | 1997-09-03 | 1997-11-20 | Fujisawa Pharmaceutical Co., Ltd. | New heterocyclic compounds |
GB9823873D0 (en) * | 1998-10-30 | 1998-12-30 | Pharmacia & Upjohn Spa | 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents |
KR100609800B1 (ko) | 1998-12-16 | 2006-08-09 | 워너-램버트 캄파니 엘엘씨 | Mek 저해제를 사용한 관절염 치료 방법 |
US7217722B2 (en) * | 2000-02-01 | 2007-05-15 | Kirin Beer Kabushiki Kaisha | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same |
PL203387B1 (pl) | 2000-07-19 | 2009-09-30 | Warner Lambert Co | Utlenione estry kwasu 4-jodofenyloaminobenzhydroksamowego |
US20020173507A1 (en) | 2000-08-15 | 2002-11-21 | Vincent Santora | Urea compounds and methods of uses |
ATE442362T1 (de) | 2001-05-24 | 2009-09-15 | Leo Pharma As | Pyridylcyanoguanidin verbindungen |
PL221491B1 (pl) | 2002-03-08 | 2016-04-29 | Eisai R&D Man Co | Związki makrocykliczne, środek farmaceutyczny zawierający te związki oraz zastosowanie tych związków |
ES2335276T3 (es) | 2002-03-13 | 2010-03-24 | Array Biopharma, Inc. | Derivados de bencimidazol alquilado n3 como inhibidores de mek. |
US20030236287A1 (en) | 2002-05-03 | 2003-12-25 | Piotrowski David W. | Positive allosteric modulators of the nicotinic acetylcholine receptor |
CA2744893A1 (en) | 2002-06-27 | 2004-01-08 | Novo Nordisk A/S | Aryl carbonyl derivatives as glucokinase activators |
CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
WO2004085433A2 (en) | 2003-03-28 | 2004-10-07 | Pharmacia & Upjohn Company Llc | Positive allosteric modulators of the nicotinic acetylcholine receptor |
PT1912636E (pt) | 2005-07-21 | 2014-07-24 | Ardea Biosciences Inc | Inibidores de n-(arilamino)-sulfonamida de mek |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
US8455513B2 (en) * | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
TWI471134B (zh) | 2007-09-12 | 2015-02-01 | Genentech Inc | 肌醇磷脂3-激酶抑制劑化合物及化療劑之組合及使用方法 |
WO2009055730A1 (en) | 2007-10-25 | 2009-04-30 | Genentech, Inc. | Process for making thienopyrimidine compounds |
CN101969949B (zh) | 2008-03-14 | 2013-12-25 | 大塚制药株式会社 | Mmp-2及/或mmp-9抑制剂 |
JP6665154B2 (ja) | 2014-07-17 | 2020-03-13 | ノース・アンド・サウス・ブラザー・ファーマシー・インベストメント・カンパニー・リミテッド | 置換尿素誘導体及びその薬学的使用 |
MA41598A (fr) | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | Composés thérapeutiques de pyridazine et leurs utilisations |
CN105481723B (zh) | 2015-04-29 | 2017-08-25 | 中国农业大学 | 一种非均相催化的烷基/苄基/芳基脲类化合物的制备方法 |
WO2018187414A1 (en) | 2017-04-05 | 2018-10-11 | The Regents Of The University Of California | Inhibitors of mtor-rictor interactions |
WO2020126968A2 (en) | 2018-12-20 | 2020-06-25 | Bayer Aktiengesellschaft | Urea derivatives |
-
2019
- 2019-08-12 DK DK19779145.2T patent/DK3837256T3/da active
- 2019-08-12 AU AU2019322325A patent/AU2019322325B2/en active Active
- 2019-08-12 US US17/268,512 patent/US11958846B2/en active Active
- 2019-08-12 CN CN201980054231.1A patent/CN112585136B/zh active Active
- 2019-08-12 SI SI201930542T patent/SI3837256T1/sl unknown
- 2019-08-12 ES ES19779145T patent/ES2946060T3/es active Active
- 2019-08-12 KR KR1020217007586A patent/KR20210047313A/ko active Search and Examination
- 2019-08-12 WO PCT/IB2019/056847 patent/WO2020035779A1/en unknown
- 2019-08-12 FI FIEP19779145.2T patent/FI3837256T3/fi active
- 2019-08-12 HU HUE19779145A patent/HUE061963T2/hu unknown
- 2019-08-12 RS RS20230377A patent/RS64238B1/sr unknown
- 2019-08-12 CA CA3107097A patent/CA3107097A1/en active Pending
- 2019-08-12 JP JP2021507613A patent/JP7328323B2/ja active Active
- 2019-08-12 EP EP23160099.0A patent/EP4219488A1/en active Pending
- 2019-08-12 PT PT197791452T patent/PT3837256T/pt unknown
- 2019-08-12 EP EP19779145.2A patent/EP3837256B1/en active Active
- 2019-08-12 PL PL19779145.2T patent/PL3837256T3/pl unknown
- 2019-08-12 MX MX2021001804A patent/MX2021001804A/es unknown
- 2019-08-12 BR BR112021002632-0A patent/BR112021002632A2/pt unknown
- 2019-08-12 LT LTEPPCT/IB2019/056847T patent/LT3837256T/lt unknown
- 2019-08-12 HR HRP20230477TT patent/HRP20230477T1/hr unknown
-
2023
- 2023-06-02 CY CY20231100266T patent/CY1126039T1/el unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2019501204A5 (es) | ||
HRP20230477T1 (hr) | Spojevi i pripravci uree kao inhibitori smarca2/brm-atpaze | |
Costa et al. | CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib | |
RU2010142396A (ru) | Кристаллические формы и две сольватные формы солей молочной кислоты 4-амино-5-фтор-3-[5-(4-метилпиперазин-1-ил)-1-н-бензимидазол-2-ил] хинолин-2(1н)она | |
JP2019142930A5 (es) | ||
Park et al. | Olmutinib (BI 1482694; HM61713), an EGFR mutant-specific inhibitor, in T790M+ NSCLC: efficacy and safety at the RP2D | |
JP2018516917A5 (es) | ||
JP2018510191A5 (es) | ||
JP2017516784A5 (es) | ||
CA2632286A1 (en) | Use of (r)-3-[1-(2,6-dichloro-3-fluror-phenyl)-ethoxyl]-5-(1-piperidin-4-yl-1h-pyrazol-4-yl)-pyridin-2-ylamine for treatment of cancer | |
JP2020514409A5 (es) | ||
JP2020536066A5 (es) | ||
CA2649549A1 (en) | Methods of treating cell proliferative disorders by using pyrimidinediamine compounds | |
RU2013155455A (ru) | Антитела для лечения раковых заболеваний, при которых эскспрессируется клаудин 6 | |
WO2009109605A1 (en) | Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members | |
JP2013126979A5 (es) | ||
JP2018503697A5 (es) | ||
KR20220041130A (ko) | 암 치료를 위한 병용 요법에서의 ezh2 억제 | |
JP2023531049A (ja) | Sos1阻害剤及びkras g12c阻害剤を含む抗がん剤併用療法 | |
JPWO2020035779A5 (es) | ||
JP2017526662A5 (es) | ||
JP2021520349A5 (es) | ||
HRP20220375T1 (hr) | Kombinirana terapija inhibitorom bromodomenskog i ekstraterminalnog proteina | |
CN115768423A (zh) | Egfr、kras、braf和其他靶标的抑制剂及其用途 | |
TW202333714A (zh) | 包含喹唑啉化合物之醫藥組成物 |